AUTHORS
Kwadwo Fosu, MPhil, Ngoc Tung Tran, PhD2, Feng Qu3, David H. Thompson, PhD4
AFFILIATIONS
1 Indiana University School of Medicine, Indianapolis, Indiana, United States
2 Indiana University School of Medicine, Indianapolis, Indiana, United States
3 Purdue University, West Lafayette, Indiana, United States
4 Purdue University, West Lafayette, Indiana, United States
ABSTRACT
Introduction:
Multiple myeloma (MM) is the second most common hematologic malignancy, with approximately 36,000 new cases and more than 10,000 deaths annually in the United States. Despite major therapeutic advances, including proteasome inhibitors, anti-CD38 monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapies, MM remains incurable, and most patients ultimately relapse due to residual disease, clonal evolution, and therapeutic resistance. We previously identified protein arginine methyltransferase 1 (PRMT1) as a therapeutic vulnerability in MM and showed that genetic knockout or pharmacologic inhibition of PRMT1 suppresses MM progression in vivo. However, systemic PRMT1 inhibition has been limited by toxicity, and no PRMT1 inhibitor is currently approved for cancer therapy. These limitations highlight the need for tumor-selective strategies that can target PRMT1 in MM cells while minimizing systemic exposure.
Lipid nanoparticles (LNPs) are effective non-viral vehicles for RNA delivery, but their clinical use has largely focused on liver-targeted applications. Expanding LNP technology to hematologic malignancies requires strategies that improve cell type-specific delivery within complex tissue niches such as the bone marrow. We therefore developed antibody-conjugated LNPs targeting B cell maturation antigen (BCMA), a clinically validated MM surface antigen. Here, we show that low-density conjugation of the anti-BCMA antibody, belantamab, enhances antigen binding, MM cell uptake, functional RNA delivery, and bone marrow accumulation in vivo.
Methods:
Belantamab-conjugated LNPs were generated using a tunable post-conjugation platform to produce control LNPs and BCMA-Ab-LNPs with low, medium, or high antibody densities corresponding to 0%, 0.05%, 0.2%, and 0.5% antibody-conjugation conditions. Particle size, polydispersity index, siRNA encapsulation efficiency, and storage stability were assessed by dynamic light scattering, and nanoparticle morphology was evaluated by cryo-electron microscopy. Antigen binding was measured using BCMA-coated magnetic beads and biolayer interferometry. Cellular uptake was quantified in JJN3 MM cells using Cy3-labeled siRNA. Functional RNA delivery was assessed by RT-qPCR and flow cytometry following delivery of siRNA targeting B2M. In vivo biodistribution was evaluated in NSG mice bearing disseminated MM xenografts 24 hours after intravenous administration of AF750-labeled LNPs using ex vivo fluorescence imaging. PRMT1 knockdown by LNP-delivered siRNA was assessed in JJN3 cells by western blot.
Results:
All BCMA-Ab-LNP formulations demonstrated high siRNA encapsulation efficiency and remained stable for at least 30 days at 4°C, with minimal changes in particle size, polydispersity index, encapsulation efficiency, and delivery capacity. Antibody density strongly influenced targeting performance. Low-density BCMA-Ab-LNPs showed the strongest BCMA binding compared with medium- and high-density formulations. Consistent with these binding data, low-density BCMA-Ab-LNPs mediated the most efficient cellular uptake of Cy3-siRNA in MM cells, as demonstrated by increased Cy3 mean fluorescence intensity and a higher percentage of Cy3-positive cells. Low-density BCMA-Ab-LNPs also produced the greatest functional gene silencing, significantly reducing B2M expression in MM cells. In disseminated MM xenograft-bearing mice, low-density BCMA-Ab-LNPs showed significantly enhanced bone marrow accumulation compared with non-targeted LNPs. In addition, PRMT1 siRNA-loaded LNPs efficiently reduced PRMT1 protein expression in MM cells, supporting the feasibility of RNA-based PRMT1 targeting.
Conclusion:
Low-density BCMA-targeted LNPs provide an effective platform for selective RNA delivery to MM cells, with enhanced antigen binding, cellular uptake, functional gene silencing, and bone marrow accumulation. These findings establish optimized BCMA-Ab-LNPs as a promising strategy for targeted RNA therapeutics in MM and provide proof of concept for LNP-mediated PRMT1 silencing selectively in MM cells. Ongoing studies will evaluate the therapeutic efficacy of optimized BCMA-Ab-LNPs carrying PRMT1 siRNA in disseminated MM xenograft and patient-derived xenograft models. More broadly, this platform may enable selective targeting of additional undruggable vulnerabilities in relapsed and refractory MM.
DISCLOSURES
Kwadwo Fosu, MPhil: No relevant conflicts of interest to declare.